Explanation
Option B is correct because AWS provides:
- Scalable compute resources that can handle the intensive computational requirements of molecular structure analysis and drug compound simulation
- Robust security features to protect sensitive research data and intellectual property
- Managed AI tools and services (such as Amazon SageMaker, AWS Deep Learning AMIs, and specialized AI services) that enable researchers to experiment with generative AI models without managing underlying infrastructure
This combination allows life-sciences teams to focus on their research rather than infrastructure management, while benefiting from AWS's reliable, scalable cloud platform.
Why other options are incorrect:
- A: AWS does not automatically validate molecular results - validation requires scientific expertise and domain-specific testing
- C: AWS cannot guarantee model fairness for all compounds as this depends on the training data and model design
- D: AWS does not replace human researchers but rather provides tools to augment their capabilities